Incruse
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse received US and EU approvals for use in COPD in April 2014. GlaxoSmithKline has also developed umeclidinium in combination with the long-acting beta 2 agonist (LABA) vilanterol; the LABA/LAMA combination is marketed under the brand name Anoro.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Incruse Ellipta : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
8 Figure 1: Incruse for COPD – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Incruse for COPD
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Incruse for COPD
13 Figure 4: Incruse sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Incruse drug profile
7 Table 2: Incruse Phase III data in COPD
14 Table 3: Incruse sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Arcapta 
Sign up to the